Ally Bridge Group (NY) LLC — 13F Holdings & Portfolio
CIK 1822947 · latest 13F-HR filed 2026-08-14
Ally Bridge Group (NY) LLC manages $113.1M in 13F-reported U.S. long-equity assets across 25 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are DFTX (16.64%), ABVX (14.73%), NERV (10.68%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 10 new positions, exited 8, added to 4, and trimmed 9.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$113.1M
Long-equity book
25
Distinct positions
2026-06-30
Filed 2026-08-14
+10 / −8 / ↑4 / ↓9
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Share-count changes vs the prior 13F.
Top Adds (vs prior quarter)
- PROMIS NEUROSCIENCES INC$2.9M +55.2%
- MINERVA NEUROSCIENCES INC$2.1M +21.1%
- WHITEHAWK THERAPEUTICS INC$924.3K +32.8%
- AN2 THERAPEUTICS INC$747.4K +41.5%
Top Trims
- OVID THERAPEUTICS INC-$4.6M -73.1%
- EUPRAXIA PHARMACEUTICALS INC-$3.1M -65.1%
- SOLID BIOSCIENCES INC-$3.0M -53.7%
- INVENTIVA SA-$1.7M -42.0%
- EDGEWISE THERAPEUTICS INC-$1.7M -33.3%
New Positions
- FIRST TRACKS BIOTHERAPEUTICS$5.7M
- AXSOME THERAPEUTICS INC$4.0M
- ASSEMBLY BIOSCIENCES INC$3.8M
- CLIMB BIO INC$3.2M
- KURA ONCOLOGY INC$3.2M
Exited Positions
- PRAXIS PRECISION MEDICINES I$10.6M
- SOLENO THERAPEUTICS INC$6.7M
- COMPASS PATHWAYS PLC$5.8M
- TARSUS PHARMACEUTICALS INC$5.7M
- ABIVAX SA$3.8M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | DEFINIUM THERAPEUTICS INC Call | DFTX | 24477V105 | $18.8M | 16.64% | 400,000 | SH |
| 2 | ABIVAX SA Call | ABVX | 00370M103 | $16.7M | 14.73% | 125,000 | SH |
| 3 | MINERVA NEUROSCIENCES INC | NERV | 603380205 | $12.1M | 10.68% | 2,175,802 | SH |
| 4 | PROMIS NEUROSCIENCES INC | PMN | 74346M505 | $8.2M | 7.22% | 620,319 | SH |
| 5 | FIRST TRACKS BIOTHERAPEUTICS | TRAX | 337185102 | $5.7M | 5.06% | 284,287 | SH |
| 6 | AXSOME THERAPEUTICS INC | AXSM | 05464T104 | $4.0M | 3.57% | 16,493 | SH |
| 7 | ASSEMBLY BIOSCIENCES INC | ASMB | 045396207 | $3.8M | 3.40% | 140,000 | SH |
| 8 | WHITEHAWK THERAPEUTICS INC | WHWK | 00032Q104 | $3.7M | 3.31% | 817,939 | SH |
| 9 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $3.4M | 2.99% | 83,300 | SH |
| 10 | CLIMB BIO INC | CLYM | 28658R106 | $3.2M | 2.87% | 249,172 | SH |
| 11 | KURA ONCOLOGY INC | KURA | 50127T109 | $3.2M | 2.81% | 290,000 | SH |
| 12 | CYTOMX THERAPEUTICS INC. | CTMX | 23284F105 | $2.9M | 2.57% | 775,000 | SH |
| 13 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $2.8M | 2.45% | 150,000 | SH |
| 14 | PALISADE BIO INC | PALI | 696389402 | $2.6M | 2.27% | 1,229,000 | SH |
| 15 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $2.6M | 2.26% | 255,959 | SH |
| 16 | AN2 THERAPEUTICS INC | ANTX | 037326105 | $2.5M | 2.25% | 526,315 | SH |
| 17 | UROGEN PHARMA LTD | URGN | M96088105 | $2.5M | 2.25% | 69,183 | SH |
| 18 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $2.5M | 2.24% | 743,958 | SH |
| 19 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $2.5M | 2.22% | 67,500 | SH |
| 20 | INVENTIVA SA | IVA | 46124U107 | $2.4M | 2.12% | 634,800 | SH |
| 21 | ALUMIS INC | ALMS | 022307102 | $2.2M | 1.90% | 76,459 | SH |
| 22 | OVID THERAPEUTICS INC | OVID | 690469101 | $1.7M | 1.49% | 624,561 | SH |
| 23 | EUPRAXIA PHARMACEUTICALS INC | EPRX | 29842P105 | $1.7M | 1.47% | 252,175 | SH |
| 24 | IBIO INC | IBIO | 451033708 | $682.8K | 0.60% | 390,147 | SH |
| 25 | TRAWS PHARMA INC | TRAW | 68232V884 | $663.0K | 0.59% | 786,236 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $113.1M | 25 | 0001193125-26-352338 |
| 2026-03-31 | 2026-05-18 | $123.8M | 28 | 0001193125-26-227559 |
| 2025-12-31 | 2026-02-17 | $96.0M | 20 | 0001193125-26-055035 |
| 2025-09-30 | 2025-11-14 | $164.2M | 25 | 0001193125-25-283054 |
NEW YORK, NY 10022